BMS Gets First Immunotherapy Approval In Neoadjuvant Lung Cancer, Quickly

 
• By Joseph Haas
  
Checkmate
Data from the CheckMate-816 study earns Bristol another indication for Opdivo • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip